Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA3011 (CAB-AXL-ADC) in metastatic NSCLC
NCT04681131Phase 2Completed
- Sponsor
- BioAtla
- Start
- Mar 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of mecbotamab vedotin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by BioAtla. Primary endpoints: Objective Response Rate at 24 months and Adverse Events or Serious Adverse Events at 24 months. Started Mar 2021; status: completed.
02
Drugs
mecbotamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04681131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04681131.